Cargando…

Calcimimetics and outcomes in CKD

In the past decade, several experimental studies demonstrated an inhibitory effect of calcimimetics on the progression of vascular calcification in animals with chronic kidney disease (CKD), in keeping with the expression of the calcium-sensing receptor (CaR) in vascular tissue. In addition, calcimi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Drüeke, Tilman B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089624/ https://www.ncbi.nlm.nih.gov/pubmed/25028644 http://dx.doi.org/10.1038/kisup.2013.90

Ejemplares similares

Calcimimetics in CKD—results from recent clinical studies
por: Schlieper, Georg, et al.
Publicado: (2008)

Strategies for Phosphate Control in Patients With CKD
por: Barreto, Fellype Carvalho, et al.
Publicado: (2019)

Introduction: expanding concepts of chronic kidney disease-mineral and bone disorder (CKD-MBD)
por: Fukagawa, Masafumi, et al.
Publicado: (2013)

Low Turnover Bone Disease in Early CKD Stages
por: Barreto, Fellype Carvalho, et al.
Publicado: (2022)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?
por: Evenepoel, Pieter, et al.
Publicado: (2022)

Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
por: Hou, Yi-Chou, et al.
Publicado: (2022)

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy
por: Frazão, João, et al.
Publicado: (2008)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease
por: Chonchol, Michel, et al.
Publicado: (2008)

Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism
por: van der Plas, Willemijn Y., et al.
Publicado: (2016)

Calcimimetic Use in Familial Hypocalciuric Hypercalcemia—A Perspective in Endocrinology
por: Marx, Stephen J.
Publicado: (2017)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
por: Damrath, John G, et al.
Publicado: (2022)

Urinary Sodium-to-Potassium Ratio and Blood Pressure in CKD
por: Alencar de Pinho, Natalia, et al.
Publicado: (2020)

Chemoenzymatic Approaches to the Synthesis of the Calcimimetic Agent Cinacalcet Employing Transaminases and Ketoreductases
por: Marx, Lisa, et al.
Publicado: (2018)

Calcimimetic restores diabetic peripheral neuropathy by ameliorating apoptosis and improving autophagy
por: Chung, You Chul, et al.
Publicado: (2018)

Effect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
por: Bokuda, Kanako, et al.
Publicado: (2021)

Relationship between patients’ characteristics and efficacy of calcimimetics for primary hyperparathyroidism in the elderly
por: Yamamoto, Koichiro, et al.
Publicado: (2022)

Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival
por: Massy, Ziad A., et al.
Publicado: (2012)

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
por: Wetmore, James B, et al.
Publicado: (2008)

The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells
por: Li, Huaifu, et al.
Publicado: (2009)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

ODP102 Indicators for the effects of calcimimetics on hypercalcemia in the elderly patients with primary hyperparathyroidism.
por: Yamamoto, Koichro, et al.
Publicado: (2022)

Bone biopsy in chronic kidney disease: still an option?
por: Drueke, Tilman B.
Publicado: (2020)

Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency
por: Törmänen, Suvi, et al.
Publicado: (2017)

A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
por: Ohya, Yuichiro, et al.
Publicado: (2018)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients
por: Bushinsky, David A., et al.
Publicado: (2008)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Therapeutic Effect of Calcimimetics on Osteoclast–Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease
por: Hung, Kuo-Chin, et al.
Publicado: (2020)

Multiple brown tumors—Forgotten pathology in times of calcimimetics: A case report and literature review
por: De La Flor Merino, José Carlos, et al.
Publicado: (2021)

Constipation in CKD
por: Sumida, Keiichi, et al.
Publicado: (2019)

Calcimimetic R-568 and Its Enantiomer S-568 Increase Nitric Oxide Release in Human Endothelial Cells
por: Bonomini, Mario, et al.
Publicado: (2012)

Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis
por: Zhang, Qian, et al.
Publicado: (2012)

Calcimimetic acts on enteric neuronal CaSR to reverse cholera toxin-induced intestinal electrolyte secretion
por: Tang, Lieqi, et al.
Publicado: (2018)

A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug
por: Leunbach, T.L., et al.
Publicado: (2021)

Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting
por: Perrone, Valentina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ss75c3vttlr8ai1g7jqem40i5d